What is Xilis?
Based in Durham, North Carolina, Xilis, Inc. is at the forefront of precision oncology, developing a proprietary MicroOrganoSphere (MOS) technology. This platform generates miniature patient tumors that replicate the full microenvironment and heterogeneity, offering an automated and scalable solution. By leveraging MOS and AI-driven algorithms, Xilis is creating a Xilis Response Score to empower oncologists with informed treatment decisions. The technology also accelerates drug development by enabling high-throughput preclinical modeling and improved clinical patient selection through analysis of authentic tumor microenvironments.
How much funding has Xilis raised?
Xilis has raised a total of $92M across 2 funding rounds:
Angel/Seed
$3M
Series A
$89M
Angel/Seed (2019): $3M with participation from Pear, Felicis Ventures, Liquid 2 Ventures, 8VC, and Guardant Health
Series A (2022): $89M led by Pear Ventures, Catalio Capital Management, FPV Ventures, EQT Life Sciences, Mubadala Capital Management, GV, Life Sciences Partners, and Alexandria Venture Investments
Key Investors in Xilis
Pear
Pear VC is an early-stage investment firm specializing in pre-seed and seed funding, supporting founders with talent recruitment, fundraising, and go-to-market strategies to foster company growth.
Catalio Capital Management
Catalio Capital Management is a New York-based investment firm focused on innovative healthcare, investing across private, public, and credit markets in breakthrough biomedical technology companies.
GV
GV is a venture capital firm that invests across multiple stages and sectors, with a focus on enterprise solutions, life sciences, consumer products, and frontier technology innovations globally.
What's next for Xilis?
The substantial enterprise-level funding and recent strategic investment signal a pivotal growth phase for Xilis. This capital infusion is expected to fuel the further development and commercialization of its precision oncology platform, particularly the Xilis Response Score. The company is well-positioned to enhance its offerings for oncologists and pharmaceutical partners, aiming to significantly improve cancer care outcomes and expedite the drug discovery pipeline. Continued expansion of its technological capabilities and market penetration will be key strategic priorities.
See full Xilis company page
